Gametogenesis

Spermatogenesis

- Begins at: Puberty.
- Occurs in: Seminiferous tubules.
- Size of sperms: 50–60 microns.
- Fertilizable span: 48–72 hours.
- Time to form spermatogenesis: 70–75 days (72 days).
- Sperms attain maturity in: Proximal end of epididymis.
- Sperms attain motility in: Distal end of epididymis.
- Time for sperm maturation: 12–14 days.
- Total time to form mature sperm: 90 days (74 + 14 days).
Oogenesis

- Begins: Intrauterine.
- Fertilizable span of ova: 12–24 hours.
- Size of mature follicle: 18–20 mm (Graafian Follicle).
- Number of follicles:
- Maximum: 6–7 million at 5th month of intrauterine life (20 weeks of pregnancy).
- At birth: 1–2 million.
- Puberty: 4–5 lakh.
- Follicles undergo apoptosis.
Menstrual Cycle
- More cycles in a year
- Polymenorrhea
- Less cycles in a year
- Oligomenorrhea
- Interval >38 days apart
First Half of Cycle
- Also called: Proliferative/Follicular phase
- Main hormone: Estrogen.
- Ovarian cycle initiated by: FSH.
Hormones formed by ovarian granulosa cells:
- Estrogen (E2) (during follicular phase)
- Inhibin B.
- AMH (Small antral & pre-antral follicles).
- Glycoprotein hormone
- Gene for MIS/AMH
- Chromosome 19
- Produced by
- Sertoli cells at 7 weeks
- Granulosa cells of preantral and small antral follicles
- Function: Regression of Mullerian Duct in males.
- Best test for Ovarian reserve
- Done any day
- 1 - 3 = Normal
- High AMH
- > 3: PCOS
- > 3.3: High risk of OHSS
- Good outcome of IVF
- Low AMH
- <1 = Suggestive of POI (Poor Ovarian reserve)
- <0.5 = Diagnostic of POI
Applied aspect
- Tumor marker for granulosa cells
- Inhibin
- AMH (New marker)
- Granulosa tumor → feminising tumor
- Estrogen effect on FSH:
- Negative.
- Estrogen effect on LH:
- Negative
- Positive: when >200 pg for 48 hrs → LH Surge.
- Inhibin effect on FSH:
- Negative.
LH Surge


- Initiated by: Estrogen (>200 pg for 48 hrs).
- Maintained by: Estrogen + progesterone.
- Before ovulation: Both LH & FSH surge.
- Ovulation due to: LH surge.
- LH acts on Theca cells to produce Androgens.
- Androgens convert to Estrogen (E2).
- In granulosa cells: Androgens convert to Estrogen(E2).
- In adipose tissue: Androgens convert to E1
Ovulation
- Primary oocyte differentiates to Secondary oocyte/egg.
- Follicle forms Corpus luteum.
Time Between Peaks

- LH surge and ovulation: 32–36 hours (Best), 24–36 hours.
- LH peak and ovulation: 10–12 hours.
- Estrogen peak and LH peak: 12–24 hours.
Second Half of Cycle

- Also called: Secretory/Luteal phase.
- Main hormone: Progesterone.
Progesterone
- In low concentration: +ve on LH, FSH.
- In high concentration: -ve on LH, FSH.
- Duration of luteal phase fixed to: 14 days.
Corpus Luteum
- In non-pregnant females:
- Maintained by LH.
- Life span 12–16 days.
- In pregnant females: Maintained by hCG.
- Hormone which prevents luteolysis: hCG.
- Maximum size and activity seen on: 8 days after ovulation (D-22).
- Maximum progesterone seen on: D-22.
- Minimum LH & FSH seen on: D-22.
- All tests for ovulation done on: D-22 = 1 week before menstruation.
- Day of ovulation: 14 days prior to next menstruation (Length of cycle – 14 days).
- Pain at time of ovulation (mid-cycle abdominal pain):
- mittelschmerz syndrome.
Estrogen
- Synthetic
- EE
- CEE
- Physiological
- E1, E2, E3
Potency
- Ethinyl Estradiol (EE) >
- Conjugated Equine Estrogen (CEE) >
- Estradiol (E2) >
- Estrone (E1) >
- Estriol (E3)
Common Estrogen Types
Condition | Estrogen Most Common/Specific |
Most common synthetic Estrogen in OCP | EE |
Most common synthetic Estrogen in HRT | 17-beta estradiol |
Most common in reproductive age female | E2 (Estradiol) |
Most common in pregnancy | E2 |
Most specific in pregnancy, Synthesised by Placenta [From DHEA from fetal adrenal gland] | E3 |
Most common in menopausal female, PCOS | E1 (Estrone) |
Low Estrogen
- POI
- Menopause
- Gonadal dysgenesis
- Sheehan’s Syndrome
- Kallman’s syndrome
Progesterone challenge test is Negative
- If Low Estrogen
- Progesterone can only act on Estrogen primed endometrium
- Normal Estrogen
- Ascherman syndrome
- d/t no endometrium
- [Positive in PCOS]
Source of Estrogen + Progesterone :
- Before 8 weeks:
- Corpus luteum of pregnancy
- Made and maintained by LH
- After 8 weeks:
- Placenta
Estrogen
Target Organ | Actions |
Uterus (Estrogen dominant) | • Increases blood flow. • Increases contractility, increases excitability. • Menstruation |
Vagina | • Vaginal Cornification |
Cervix | • Cervical mucus production |
Secondary sexual characteristics | • Creates female body contour. • Promotes fat distribution in breast & buttocks. • DO NOT CAUSE PUBIC OR AXILLARY HAIR GROWTH |
Breast | • Promotes growth. • Aids ductal proliferation. |
Bone | • Produces Osteoprotegerin (inhibitor of RANK ligand). • ↓↓ osteoclast differentiation → ⛔ bone resorption → Protects bone |
Liver | • ↓↓ plasma LDL cholesterol |
CVS | • ⛔ platelet activation → ↓ Clot formation • Promotes vasodilation by increasing NO |
CNS | Neuroprotective: • ⛔ neuronal cell death |
Kidneys | • Causes salt & water retention |
Progesterone
Target Organ | Actions |
Uterus | Anti-estrogenic action: • Makes uterus less active, less excitable, less contractile |
Breast | • Promotes lobulo-alveolar (gland) growth |
CNS | Thermogenic action: • ↑↑ Basal Body Temperature (BBT) by 0.5-1°C during ovulation. |
Respiration | • Stimulates respiration → Leads to CO2 washout → ↓↓ alveolar PCO2 levels |
Kidneys | Causes Natriuresis: • Promotes salt & water excretion • (Only steroid hormone → cause Natriuresis) |
NOTE
- Androgens are formed in Ovary
- In Theca Interna cells
- Not DHT, DHEA
- Testosterone → 5α reductase enzyme→ Di-hydro testosterone (DHT) (more potent).
- Aromatase from granulosa cells
- convert to Estradiol (E2) → most potent
- Aromatase from peripheral fat
- convert to Estrone (E1)
NOTE

Associations of Estrogen Dependent Conditions
Estrogen Dependent Conditions
- Fibroid
- Endometriosis
- Endometrial Carcinoma
- Ovarian Carcinoma
Common Risk Factors
- Nulliparity
- Obesity
- Early menarche
- Late menopause
Protective Factors
- Multiparity
- Pregnancy
- Physical exercise
- Smoking
- Due to aromatase inhibition
Incessant Ovulation Theory
- Definition:
- Increased ovulation → Leads to increased risk of ovarian carcinoma
- Variable risk
- PCOS
- Ovulation inducing drugs
- Protective factors:
- OCP (Oral Contraceptive Pills)
- Breastfeeding
Key Clinical Notes
- Virilizing ovarian tumor: Arrhenoblastoma
- Most common post-menopausal bleeding
- M/C cause in India: Cervical cancer.
- M/C cause:
- Polyp (37%)
- Deepthi Bahl → Still Endometrial Atrophy > Plyp
- 2nd M/C cause: Endometrial atrophy/Senile endometriosis (30%).
Dysmenorrhea
Pain at Time of Menstruation
Primary/Spasmodic Dysmenorrhea
- Pathology: Progesterone (relaxant) withdrawal causes vasoconstriction → Release of PGF2α → leading to pain (No pelvic pathology).
- Presentation:
- Young female
- c/o pain since menarche except initial few cycles
- Anovulatory
- Pain Location: Suprapubic area (Generalized).
- Pain Character:
- Just before or at menstruation;
- relieved within 72 hours.
- Pain Progression:
- Pain decreases on its own;
- After physical act;
- Marriage;
- Child birth.
- P/V: Normal.
- Rx: NSAIDs or OCPs (makes the cycles anovulatory).
Secondary/Congestive Dysmenorrhea
- Causes: Pelvic pathologies.
- Endometriosis (m/c).
- Adenomyosis.
- Fibroid.
- Pelvic inflammatory disease.
- Presentation:
- Reproductive age group female (33 years),
- C/o pain at the time of menstruation,
- Previously No h/o pain.
- Pain Location: Localized.
- Pain Character: Begins much before menstruation, and remains after menses.
- Pain Progression: Pain increases progressively.
- P/V: Abnormal.
- Rx: Manage the cause.
Drugs for Endometriosis/Dysmenorrhea
- Hyperestrogenic condition:
- Rx aims to decrease estrogen
- Minimal–mild:
- 1st line: NSAIDs/OCPs.
- 2nd line: Progesterone (downregulates estrogen receptor).
- 3rd line: GnRH continuous.
- If no relief: Laparoscopic management.
- Moderate–Severe:
- 1st line: Continuous GnRH.
- If no relief: Laparoscopic management.